Pressmeddelande

SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners

SenzaGen, a developer and provider of advanced non-animal test methods based on genomics and machine learning, continues to strengthen its position as a thought leader in non-animal toxicology. From March 22–25, 2026, the company will present new scientific data at the SOT 65th Annual Meeting & ToxExpo, the world’s largest toxicology conference, together with several leading industry partners.

SOT is a central scientific forum where SenzaGen will highlight how the GARD® platform is being used by industry and how global demand for advanced non-animal test methods continues to grow. During the conference, the company will present the platform’s broad applicability and its unique strengths for assessing complex and challenging substances, as well as for quantitative risk assessment.

As part of the program, SenzaGen will present posters and host its own session featuring external speakers who will share their results and experiences with GARD®. These activities are organized in collaboration with several global companies including Johnson & Johnson MedTech, ExxonMobil (chemicals), Coty (fragrance and cosmetics), and Haleon (OTC pharmaceuticals), alongside researchers from SenzaGen.

“Through our program at this year’s SOT, we continue to reinforce our role as a thought leader while strengthening the position of the GARD® platform within the toxicology community. Having global companies such as ExxonMobil and Johnson & Johnson MedTech present their results on GARD® together with us reflects both the confidence in the technology and the clear shift toward non‑animal testing,” says Peter Nählstedt, President & CEO of SenzaGen.

During the conference, SenzaGen and its scientific partners will present new data within:

Skin and respiratory sensitization
Testing of challenging chemicals and formulations
Evaluation of medical device materials
Quantitative risk assessment (safe dose levels)

The SOT Annual Meeting & ToxExpo is organized by the Society of Toxicology and attracts approximately 5,000 scientists and experts from around the world each year.

Learn more about SenzaGen’s scientific program here:
https://senzagen.com/event/2026sot/

About us

SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.